Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy

Journal of Medicinal Chemistry

Volumn 52, Issue 14, 2009, Pages 4095-4098

  Zheng, Hailin ^a,c   Youdim, Moussa B H ^b   Fridkin, Mati ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c Intra Cellular Therapies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 PROPARGYLPIPERAZIN 1 YLMETHYL) 8 HYDROXYQUINOL; 5 (4 PROPARGYLPIPERAZIN 1 YLMETHYL) 8 HYDROXYQUINOLINYLDIMETHYLCARBAMATE; ACETYLCHOLINESTERASE; AMINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BUTYRYLTHIOCHOLINE; CHELATING AGENT; CHOLINESTERASE INHIBITOR; COPPER ION; DONEPEZIL; HLA 20; HLA 20A; IRON; PRODRUG; PROPARGYLAMINE; QUINOLINOL DERIVATIVE; RIVASTIGMINE; UNCLASSIFIED DRUG; ZINC ION;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG MECHANISM; DRUG RELEASE; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; NEUROPROTECTION; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; ANIMALS; BRAIN; CELL LINE, TUMOR; CELL SURVIVAL; CHELATING AGENTS; CHOLINESTERASE INHIBITORS; DRUG DESIGN; HUMANS; HYDROXYQUINOLINES; METALS; NEUROPROTECTIVE AGENTS; PIPERAZINES; PRODRUGS; RATS;

EID: 67650759968     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900504c     Document Type: Article

References (32)

1. Barnham, K. J.; Bush, A. I. Metals in Alzheimer's and Parkinson's diseases. Curr. Opin. Chem. Biol. 2008, 12, 222-228.
2. Bush, A. I. Drug development based on the metals hypothesis of Alzheimer's disease. J. Alzheimer's Dis. 2008, 15, 223--240.
3. Amit, T.; Avramovich-Tirosh, Y.; Youdim, M. B.; Mandel, S. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J. 2008, 22, 1296-1305.
4. Biran, Y.; Masters, C. L.; Barnham, K. J.; Bush, A. I.; Adlard, P. A. Pharmacotherapeutic targets in Alzheimer's disease. J. Cell. Mol. Med. 2009, 13, 61-86.
5. Rogers, J. T.; Randall, J. D.; Cahill, C. M.; Eder, P. S.; Huang, X.; Gunshin, H.; Leiter, L.; McPhee, J.; Sarang, S. S.; Utsuki, T.; Greig, N. H.; Lahiri, D. K.; Tanzi, R. E.; Bush, A. I.; Giordano, T.; Gullans, S. R. An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem. 2002, 277, 45518-45528.
6. Price, K. A.; Crouch, P. J.; White, A. R. Therapeutic treatment of Alzheimer's disease using metal complexing agents. Recent Pat. CNS Drug Discovery 2007, 2, 180-187.
7. Zheng, H.; Youdim, M. B.; Weiner, L. M.; Fridkin, M. Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons. Biochem. Pharmacol. 2005, 70, 1642-1652.
8. Charkoudian, L. K.; Pham, D. M.; Franz, K. J. A pro-chelator triggered by hydrogen peroxide inhibits iron-promoted hydroxyl radical formation. J. Am. Chem. Soc. 2006, 128, 12424-12425.
9. Schugar, H.; Green, D. E.; Bowen, M. L.; Scott, L. E.; Storr, T.; Bohmerle, K.; Thomas, F.; Allen, D. D.; Lockman, P. R.; Merkel, M.; Thompson, K. H.; Orvig, C. Combating Alzheimer's disease with multifunctional molecules designed for metal passivation. Angew. Chem., Int. Ed. 2007, 46, 1716-1718.
10. Storr, T.; Merkel, M.; Song-Zhao, G. X.; Scott, L. E.; Green, D. E.; Bowen, M. L.; Thompson, K. H.; Patrick, B. O.; Schugar, H. J.; Orvig, C. Synthesis, characterization, and metal coordinating ability of multifunctional carbohydrate-containing compounds for Alzheimer's therapy. J. Am. Chem. Soc. 2007, 129, 7453-7463.
11. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 2008, 51, 347-372.
12. Frantz, S. Drug discovery: playing dirty. Nature 2005, 437, 942-943.
13. Van der Schyf, C. J.; Youdim, M. B. Multifunctional drugs as neurotherapeutics. Neurotherapeutics 2009, 6, 1-3.
14. Sagi, Y.; Mandel, S.; Amit, T.; Youdim, M. B. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol. Dis. 2007, 25, 35-44.
15. Bar-Am, O.; Weinreb, O.; Amit, T.; Youdim, M. B. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J. 2005, 19, 1899-1901.
16. Avramovich-Tirosh, Y.; Reznichenko, L.; Mit, T.; Zheng, H.; Fridkin, M.; Weinreb, O.; Mandel, S.; Youdim, M. B. Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron-chelating-antioxidants, M-30 and green tea polyphenol, EGCG. Curr. Alzheimer Res. 2007, 4, 403-411.
17. Avramovich-Tirosh, Y.; Amit, T.; Bar-Am, O.; Zheng, H.; Fridkin, M.; Youdim, M. B. Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J. Neurochem. 2007, 100, 490-502.
18. Gal, S.; Fridkin, M.; Amit, T.; Zheng, H.; Youdim, M. B. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selectivemonoamine oxidase-ab inhibitory activity for Parkinson's disease. J. Neural Transm., Suppl. 2006, 447-456.
19. Zheng, H.; Youdim, M. B.; Weiner, L. M.; Fridkin, M. Synthesis and evaluation of peptidic metal chelators for neuroprotection in neurodegenerative diseases. J. Pept. Res. 2005, 66, 190-203.
20. Zheng, H.; Weiner, L. M.; Bar-Am, O.; Epsztejn, S.; Cabantchik, Z. I.; Warshawsky, A.; Youdim, M. B.; Fridkin, M. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg. Med. Chem. 2005, 13, 773-783.
21. Gal, S.; Zheng, H.; Fridkin, M.; Youdim, M. B. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J. Neurochem. 2005, 95, 79-88.
22. Zheng, H.; Gal, S.; Weiner, L. M.; Bar-Am, O.; Warshawsky, A.; Fridkin, M.; Youdim, M. B. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem. 2005, 95, 68-78.
23. Youdim, M. B. H.; Fridkin, M.Zheng, H.; Warshawsky, R.; Warshawsky, A. Neuroprotective Iron Chelators and Pharmaceutical Compositions Comprising Them. WO/2004/041151, May 21, 2004.
24. Youdim, M. B.; Zheng, H.; Fridkin, M. Neuroprotective Multifunctional Compounds and Pharmacutical Compositions Comprising Them. U.S. Patent pending.
25. Munoz-Torrero, D. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease. Curr. Med. Chem. 2008, 15, 2433-2455.
26. Zhang, H. Y.; Yan, H.; Tang, X. C. Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase. Cell. Mol. Neurobiol. 2008, 28, 173-183.
27. del Monte-Millan, M.; Garcia-Palomero, E.; Valenzuela, R.; Usan, P.; de Austria, C.; Munoz-Ruiz, P.; Rubio, L.; Dorronsoro, I.; Martinez, A.; Medina, M. Dual binding site acetylcholinesterase inhibitors: potential new disease-modifying agents for AD. J. Mol. Neurosci. 2006, 30, 85-88.
28. Garcia-Palomero, E.; Munoz, P.; Usan, P.; Garcia, P.; Delgado, E.; De Austria, C.; Valenzuela, R.; Rubio, L.; Medina, M.; Martinez, A. Potent beta-amyloid modulators. Neurodegener. Dis. 2008, 5, 153-156.
29. Bar-On, P.; Millard, C. B.; Harel, M.; Dvir, H.; Enz, A.; Sussman, J. L.; Silman, I. Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. Biochemistry 2002, 41, 3555-3564.
30. Kryger, G.; Silman, I.; Sussman, J. L. Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure 1999, 7, 297-307.
31. Greig, N. H.; Utsuki, T.; Yu, Q.; Zhu, X.; Holloway, H. W.; Perry, T.; Lee, B.; Ingram, D. K.; Lahiri, D. K. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr. Med. Res. Opin. 2001, 17, 159-165.
32. Patani, G. A.; Pang, Y. P.; Chien, Y. W. A potent and selective tacrine analog - biomembrane permeation and physicochemical characterization. Pharm. Dev. Technol. 2005, 10, 525-538.